<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="/static/rendered_html/uslm.css">
        <link rel="stylesheet" href="/static/rendered_html/style.css">
        <script src="https://kit.fontawesome.com/2ce1080035.js" crossorigin="anonymous"></script>
        <script lang="text/javascript" src="/static/rendered_html/omni.js" defer></script>

        <!-- Table of Contents button section sheet. Would ideally be a working breadcrumb --> 
        <img src="../omni.jpg" alt="Omnibuster" style="width:100%">
        <ul class="breadcrumb" style="text-align:center">
            <!-- TODO GENERALIZE THIS --> 
            <li><a href="index.html"> Table of Contents</a></li>
            
                <li> Title II </a></li>
            
                <li> Subtitle D </a></li>
            
                <li> Section 2304 </a></li>
            
        </ul>


        <!-- <title> Omnibuster </title>
 -->
    </head>

    <body>
        <br><br><br>
        <div class="section">
            <div class="buttons">
                <div class="navbar">
                    <div>
                        <button onclick="highlightSelection();">Highlight Text</button>
                    </div>
                    <div>
                        <button onclick="annotateSelection();">[Not working] Annotate Text</button>
                    </div> 
                </div>
            </div>
            <p> 
                <section id="d2034e5915" identifier="/us/bill/117/hr/1319/tII/stD/s2304" style="-uslm-lc:I650144">
<num value="2304">SEC. 2304. </num>
<heading>FUNDING FOR COVID–19 VACCINE, THERAPEUTIC, AND DEVICE ACTIVITIES AT THE FOOD AND DRUG ADMINISTRATION.</heading>
<content style="-uslm-lc:I650120">   In addition to amounts otherwise available, there is appropriated to the Secretary for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, $500,000,000, to remain available until expended, to be used for the evaluation of the continued performance, safety, and effectiveness, including with respect to emerging COVID–19 variants, of vaccines, therapeutics, and diagnostics approved, cleared, licensed, or authorized for use for the treatment, prevention, or diagnosis of COVID–19; facilitation of advanced continuous manufacturing activities related to production of vaccines and related materials; facilitation and conduct of inspections related to the manufacturing of vaccines, therapeutics, and devices delayed or cancelled for reasons related to COVID–19; review of devices authorized for use for the treatment, prevention, or diagnosis of COVID–19; and oversight of the supply chain and mitigation of shortages of vaccines, therapeutics, and devices approved, cleared, licensed, or authorized for use for the treatment, prevention, or diagnosis of COVID–19 by the Food and Drug Administration.</content>
</section>
            </p>
        </div>  

        <!-- previous section -->
        <button onclick="location.href='section_s2303.html'" id="ls-btn-prev-sec" title="go to previous section">
            <i class="fas fa-angle-left"></i>
        </button>
        <!-- end previous section -->

        <!-- next section -->
        <button onclick="location.href='section_s2305.html'" id="ls-btn-next-sec" title="go to next section" data-ls-target-index="2">
            <i class="fas fa-angle-right"></i>
        </button>
        <!-- end next section -->

    </body>
